Jul 31, 2013 7:00am EDT NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
Jul 25, 2013 7:00am EDT NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
